Clinical trials: Liver Diseases, Alcoholic
Non-alcoholic Fatty Liver
High-intensity Interval Training Versus Moderate Intensity Continuous Training on Gut Microbiota in Non-alcoholic Fatty Liver
To compare High-Intensity Interval Training versus moderate intensity continuous training on gut microbiota in Non- Alcoholic Fatty Liver.
- Trial name
- NCT07697313
- Testing
- High intensity interval training, moderate intensity continuous training, Mediterranean diet
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Horus University
Non-alcoholic Fatty Liver Disease, Type 2 Diabetes
Role of New Adipokines and Hepatokines in Prediction of Patients With Metabolic Syndrome or NAFLD
To investigate the predictive roles of adipokines and hepatokines to detect non-alcoholic fatty liver disease (NAFLD), diabetes, or dyslipidmia.
- Conditions
- Non-alcoholic Fatty Liver Disease, Type 2 Diabetes, Metabolic Syndrome
- Trial name
- NCT02285218
- Testing
- serum blood sampling
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Yonsei University
Non-Alcoholic Fatty Liver Disease
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
The purpose of the study is to assess the safety and tolerability of ALT-801 in diabetic and non-diabetic subjects with overweight and obese and non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT05006885
- Testing
- ALT-801
- Where
- 15 sites in United States
- Volunteers
- 95 people
- Sponsor
- Altimmune, Inc.
Non-Alcoholic Fatty Liver Disease (NAFLD)
Proliverenol Supplementation for Non-Alcoholic Fatty Liver Disease (NAFLD)
This is a 4-arm, prospective, randomized, double-blind, double-dummy, and placebo-controlled clinical study comparing Proliverenol at a dose of 500 mg twice daily; Proliverenol at a dose of 1000 mg once daily; Proliverenol at a…
- Trial name
- NCT06127225
- Testing
- Proliverenol
- Where
- Indonesia
- Volunteers
- 80 people
- Sponsor
- Dexa Medica Group
NAFLD, NASH - Nonalcoholic Steatohepatitis
The Franciscus Obesity NASH Study
The purpose of this study is to evaluate Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) changes in terms of steatosis and elasticity in patients with morbid obesity 1, 3 and 5 years after…
- Conditions
- NAFLD, NASH - Nonalcoholic Steatohepatitis, Obesity, Morbid
- Trial name
- FONS (NCT05499949)
- Testing
- NASH screening, Cardiac dysfunction screening, Liver biopsy
- Where
- Netherlands
- Volunteers
- 300 people
- Sponsor
- Franciscus Gasthuis
Diabetes Mellitus Type 2
Medium-term Effects of a Polyphenol-rich Beverage Based on Red Grape Pomace Extract on Non-alcoholic Fatty Liver Disease, Cardiometabolic Risk Profile and Gut Microbiota in Subjects with Type 2 Diabetes
Nonalcoholic fatty liver disease (NAFLD) is a liver disease characterized by an abnormal accumulation of fat not due to alcohol or drug consumption that can evolve into steatohepatitis (NASH), fibrosis and cirrhosis.
- Trial name
- PoLiFat (NCT06895018)
- Testing
- Supplementation with Polyphenol Rich Drink
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Federico II University
Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
The primary aim of the study is to determine the impact on hepatic steatosis of replacing premeal rapid-acting insulin for exenatide (Byetta) while maintaining bedtime long-acting detemir (Levemir) insulin in well-controlled…
- Trial name
- NCT01006889
- Testing
- Exenatide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Florida
NAFLD
Effects of Tomato Products in Children With NAFLD
CONTROLLED TRIAL ON THE EFFECT OF TOMATO PRODUCTS IN OBESE CHILDREN WITH NON ALCOHOLIC FATTY LIVER DISEASE Aim of the study To evaluate the effect of the addition of a daily dose of lycopene enriched tomato sauce on the progress…
- Trial name
- NCT03463967
- Testing
- Lycopene-enriched tomato juice, Energy-restricted diet
- Where
- Italy
- Volunteers
- 61 people
- Sponsor
- Federico II University
NAFLD
Evaluate the Efficacy and Safety of LivPhcD Capsules in the NAFLD Subjects
Non-alcoholic fatty liver disease (also called NAFLD) is a disease in which excessive fat accumulates in the liver of a patient without a history of alcohol abuse.
- Trial name
- NCT05930093
- Testing
- 2 cap.LivPhcD/per day, 4 cap.LivPhcD/per day, 6 cap.LivPhcD/per day
- Where
- Taiwan
- Volunteers
- 110 people
- Sponsor
- TCM Biotech International Corp.
Alcoholic Cirrhosis
National Cohort of Uncomplicated Alcoholic Cirrhosis
Hepatocellular carcinoma (HCC) is a major public health problem, whose incidence is increasing in developed countries and is the leading cause of death in patients with cirrhosis.
- Trial name
- CIRRAL (NCT01213927)
- Where
- France
- Volunteers
- 709 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
NAFLD, MASLD
NAFLD Clinical Care Pathway
Non-alcoholic fatty liver disease (NAFLD) is a new condition that has become the most common chronic liver disease in the world and a main cause of liver cirrhosis, liver failure and liver cancer.
- Trial name
- NCCP (NCT06671886)
- Testing
- E-trigger
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Steatohepatitis, Nonalcoholic
The COherence of Scatter Identification and Exclusion Algorithm Study
Non-alcoholic fatty liver disease (NAFLD) is currently the most common liver condition worldwide; approximately 55% of the world population will have NAFLD by 2040.
- Trial name
- COSIE (NCT06975579)
- Testing
- Ultrasound image processing
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Institute of Cancer Research, United Kingdom
Non-Alcoholic Fatty Liver Disease
NAFLD Study: US vs Liver Biopsy
Evaluate the diagnostic accuracy of the new ultrasound software vs hepatic histology, the current reference standard for the diagnosis of NAFLD and NASH in 20 obese patients (BMI> 30) candidates for laparoscopic bariatric surgery…
- Trial name
- NAFLD (NCT04101162)
- Testing
- shear waves elastography; liver biopsy
- Where
- Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
NAFLD, Hiv
Lifestyle Modification Programme for HIV-infected Individuals With Fatty Liver
Non-alcoholic fatty liver disease (NAFLD) is rising in prevalence, and will likely become the predominant cause of chronic liver disease in HIV-infected individuals.
- Trial name
- NCT03913351
- Testing
- Lifestyle modification
- Where
- Hong Kong
- Volunteers
- 96 people
- Sponsor
- Chinese University of Hong Kong
Alcoholic Hepatitis
Effect of Omega 5 Fatty Acid as an Adyuvant Treatment to Prednisone in Patients With Severe Alcoholic Hepatitis
In Mexico, alcoholic liver disease is the fourth cause of mortality (INEGI). Patients with severe alcoholic hepatitis have a high mortality at 28 days and 6 months, patients receiving standard therapy with prednisone that are non…
- Trial name
- NCT03732586
- Testing
- Omega 5 fatty acid supplement
- Where
- 2 sites in Mexico
- Volunteers
- 40 people
- Sponsor
- Hospital General Dr. Manuel Gea González
NAFLD, Obesity, Adolescent
Impact of Weight Loss Surgery in Adolescents With NAFLD
This study will assess the impact of weight loss surgery (WLS) on non-alcoholic fatty liver disease (NAFLD) in adolescents as well as the interaction between NAFLD and cardiometabolic risk.
- Trial name
- AWLS (NCT02952170)
- Testing
- MRI
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis
Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST)
GLP-1 analogues represent new treatments in diabetes that cause weight loss. Their effect on NASH in humans is unknown. A decrease in Alanine Aminotransferase (ALT) has been reported in pooled Exenatide/Placebo and…
- Trial name
- REALIST (NCT03648554)
- Testing
- dulaglutide (TRULICITY®) 1.5 mg, reinforced dietary monitoring
- Where
- 9 sites in France
- Volunteers
- 93 people
- Sponsor
- Central Hospital, Nancy, France
Steatosis of Liver, NASH - Nonalcoholic Steatohepatitis
The Liver in the World Trade Center Health Program General Responder Cohort and Controls
This project investigates whether exposure to the World Trade Center Attack is a risk factor for liver injury.
- Trial name
- NCT03858920
- Testing
- Fibroscan of Liver, Low-dose non-contrast CT
- Where
- United States
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Coronary Disease, Non-alcoholic Fatty Liver Disease
Non-invasive Liver Screening for Risk Assessment for Coronary Heart Disease
Background: Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome, which is one of the major risk factors of coronary heart disease (CHD).
- Conditions
- Coronary Disease, Non-alcoholic Fatty Liver Disease, Elasticity Imaging Techniques
- Trial name
- NILS-R-CHD (NCT02779946)
- Testing
- Fibro Scan, PNPLA3
- Where
- Germany
- Volunteers
- 216 people
- Sponsor
- University of Leipzig
NAFLD/MAFLD, Liver Fibrosis
Impact of Fluid Status on Liver Elastography and T1-mapping Results in Patients Undergoing CMR.
Correlation between CMR T1-times, liver T1-times, fibroscan and fluid status to identify the correlation and pathogenesis of liver disease in patients with heart disease.
- Conditions
- NAFLD/MAFLD, Liver Fibrosis, CMR
- Trial name
- NCT05239260
- Testing
- CMR
- Where
- Austria
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna